160 related articles for article (PubMed ID: 12871160)
1. Selective ACAT inhibitors as promising antihyperlipidemic, antiathero-sclerotic and anti-Alzheimer drugs.
Giovannoni MP; Piaz VD; Vergelli C; Barlocco D
Mini Rev Med Chem; 2003 Sep; 3(6):576-84. PubMed ID: 12871160
[TBL] [Abstract][Full Text] [Related]
2. Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs.
Leon C; Hill JS; Wasan KM
Pharm Res; 2005 Oct; 22(10):1578-88. PubMed ID: 16180116
[TBL] [Abstract][Full Text] [Related]
3. Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis.
Chang C; Dong R; Miyazaki A; Sakashita N; Zhang Y; Liu J; Guo M; Li BL; Chang TY
Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):151-6. PubMed ID: 16518538
[TBL] [Abstract][Full Text] [Related]
4. Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs.
Alegret M; Llaverias G; Silvestre JS
Methods Find Exp Clin Pharmacol; 2004 Sep; 26(7):563-86. PubMed ID: 15538545
[TBL] [Abstract][Full Text] [Related]
5. Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents.
Tomoda H; Doi T
Acc Chem Res; 2008 Jan; 41(1):32-9. PubMed ID: 17803269
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents.
Sliskovic DR; White AD
Trends Pharmacol Sci; 1991 May; 12(5):194-9. PubMed ID: 1862535
[TBL] [Abstract][Full Text] [Related]
7. [MTP inhibitors and ACAT inhibitors. An update].
Ohashi K
Nihon Rinsho; 2002 May; 60(5):975-83. PubMed ID: 12030002
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
[TBL] [Abstract][Full Text] [Related]
9. Carotid atherosclerosis progression and ACAT inhibition.
Parini P; Eriksson M; Rudel LL
JAMA; 2009 Jul; 302(3):255; author reply 256-7. PubMed ID: 19602681
[No Abstract] [Full Text] [Related]
10. Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.
Miyazaki A; Sakai M; Sakamoto Y; Horiuchi S
Curr Opin Investig Drugs; 2003 Sep; 4(9):1095-9. PubMed ID: 14582454
[TBL] [Abstract][Full Text] [Related]
11. ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease.
Shibuya Y; Chang CC; Chang TY
Future Med Chem; 2015; 7(18):2451-67. PubMed ID: 26669800
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of R-755, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in cholesterol-fed rats, hamsters and rabbits.
Matsui Y; Horiuchi K; Yamamoto K; Kanai K
Jpn J Pharmacol; 2001 Apr; 85(4):423-33. PubMed ID: 11388647
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Llaverías G; Laguna JC; Alegret M
Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?
López-Farré AJ; Sacristán D; Zamorano-León JJ; San-Martín N; Macaya C
Cardiovasc Ther; 2008; 26(1):65-74. PubMed ID: 18466422
[TBL] [Abstract][Full Text] [Related]
15. Acyl coenzyme A:cholesterol acyltransferase inhibition: potential atherosclerosis therapy or springboard for other discoveries?
Heinonen TM
Expert Opin Investig Drugs; 2002 Nov; 11(11):1519-27. PubMed ID: 12437499
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis?
Heinonen TM
Curr Atheroscler Rep; 2002 Jan; 4(1):65-70. PubMed ID: 11772425
[TBL] [Abstract][Full Text] [Related]
17. Carotid atherosclerosis progression and ACAT inhibition.
Dimmitt S; Watts G
JAMA; 2009 Jul; 302(3):255-6; author reply 256-7. PubMed ID: 19602680
[No Abstract] [Full Text] [Related]
18. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness.
Lada AT; Davis M; Kent C; Chapman J; Tomoda H; Omura S; Rudel LL
J Lipid Res; 2004 Feb; 45(2):378-86. PubMed ID: 14617738
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Miyazaki A; Kanome T; Watanabe T
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866
[TBL] [Abstract][Full Text] [Related]
20. Isoform-specific inhibitors of ACATs: recent advances and promising developments.
Ohshiro T; Tomoda H
Future Med Chem; 2011 Dec; 3(16):2039-61. PubMed ID: 22098352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
